Abstract

BackgroundThe neutrophil-to-lymphocyte ratio (NLR) is a useful marker of inflammation. However, the prognostic function of the NLR in patients with carbapenem-resistant Klebsiella pneumoniae (CRKP) blood stream infection (BSI) remains largely unknown. The aim of this study was to explore the potential relationship between the NLR and mortality in these patients.MethodsWe performed a retrospective cohort study based on data retrieved from the computerized patient record system in a tertiary hospital from 1 January 2017 to 31 October, 2020. A total of 134 inpatients with CRKP BSI were enrolled in this study, including 54 fatal cases and 80 survival cases, 28 days after the onset of CRKP BSI. A logistic analysis was performed to assess the association between the NLR on the 4th day and 28-day mortality. Multivariate analyses were used to control for the confounders.ResultsThe overall 28-day mortality rate of patients with a CRKP BSI episode was 40.3% (54/134). We conducted a multivariate analysis of the data of 134 patients and found that the NLR on the 4th day [odds ratio (OR) 1.148, 95% confidence interval (CI) 1.076–1.225, p < 0.001] and antibiotic exposure before BSI onset (OR 3.847, 95% CI 1.322–11.196, p = 0.013) were independent risk factors for 28-day mortality of patients with CRKP BSI, while appropriate initial therapy (AIT, OR 0.073, 95% CI 0.017–0.307, p < 0.001) was an independent protective factor. Among patients treated with AITs, the Cox proportional hazards regression analysis revealed a significant difference in prognosis (p = 0.006) between the ceftazidime/avibactam contained (CAZ) group and non CAZ-AVI groups. After dividing the non CAZ-AVI group into the tigecycline (TGC), colistin (COL), and TGC + COL groups, there were no differences between the CAZ-AVI group and the TGC group (p = 0.093), but CAZ-AVI group showed lower 28-day mortality than COL (p = 0.002) and TGC + COL (p = 0.002) groups. Meanwhile, there was no difference in NLR on the 1st day (p = 0.958) of patients in different groups but significant difference in NLR on the 4th day (p = 0.047).ConclusionsThe NLR on the 4th day is a readily available and independent prognostic biomarker for patients with CRKP BSI. This marker may have the potential for use in evaluating the efficacy of different anti-infection therapy strategies at an early stage.

Highlights

  • Klebsiella pneumoniae is one of the most common bacteria in the class Enterobacteriales; it is ubiquitous and can cause nosocomial infections, such as pneumonia, urinary tract infection, catheterrelated infection, and blood stream infection (BSI) [1, 2]

  • After considering the univariate relationship with outcome and clinical relevance, we conducted a multivariate analysis of these 134 patients and found that the neutrophil-to-lymphocyte ratio (NLR) on the 4th day and antibiotic exposure

  • We found that the NLR value with the highest

Read more

Summary

Introduction

Klebsiella pneumoniae is one of the most common bacteria in the class Enterobacteriales; it is ubiquitous and can cause nosocomial infections, such as pneumonia, urinary tract infection, catheterrelated infection, and blood stream infection (BSI) [1, 2]. With the increasing clinical use of carbapenems over the last few years, carbapenem-resistant K. pneumoniae (CRKP) has risen at an alarming rate, and is considered a serious threat to human health worldwide. It has been recorded in the China antimicrobial surveillance network that from 2005 to 2021, the proportion of K. pneumoniae isolates resistant to imipenem increased from 3.0 to 25.5% in China (http://www.chinets.com/). Patients infected with CRKP have higher mortality rates than those infected with carbapenem-susceptible Klebsiella pneumonia (CSKP) [6]. The prognostic function of the NLR in patients with carbapenem-resistant Klebsiella pneumoniae (CRKP) blood stream infection (BSI) remains largely unknown. The aim of this study was to explore the potential relationship between the NLR and mortality in these patients

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call